SCHEMBL24316034

SCHEMBL24316034

Cc1cccc2c1CCCN2I

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 1/20 0.49
▸ HTR2C P28335 1/20 0.42
▸ HTR2B P41595 1/20 0.42
▸ ALOX5 P09917 2/20 0.40
▸ CNR2 P34972 1/20 0.39
▸ ADRB1 P08588 2/20 0.37
▸ ALOX12 P18054 1/20 0.37
▸ AADAT Q8N5Z0 1/20 0.36
▸ DRD2 P14416 1/20 0.35
▸ DRD4 P21917 1/20 0.35
▸ RXRA P19793 1/20 0.34
▸ RXRB P28702 1/20 0.34
▸ RXRG P48443 1/20 0.34
▸ DDB1 Q16531 1/20 0.34
▸ CRBN Q96SW2 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ ADRA1D P25100 1/20 0.34
▸ ADRA1A P35348 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19964476 0.90 NOTUM (0.54) NOTUMHTR2CHTR2BALOX5CNR2
SCHEMBL23346738 0.79 KEAP1 (0.40) NOTUMALOX12MEN1LMNAKMT2A
SCHEMBL24316049 0.79 NOTUM (0.51) NOTUMHTR2CHTR2BAADATDRD2
SCHEMBL22433896 0.79 ALOX5 (0.45) NOTUMHTR2CHTR2BALOX5DRD2
SCHEMBL8276444 0.78 NOTUM (0.50) NOTUMHTR2CHTR2BALOX5CNR2
SCHEMBL19960798 0.74 NOTUM (0.46) NOTUMHTR2CHTR2BALOX5CNR2
SCHEMBL31170836 0.73 NOTUM (0.49) NOTUMHTR2CHTR2BALOX5CNR2
SCHEMBL256749 0.72 NOTUM (0.56) NOTUMHTR2CHTR2BALOX5CNR2
SCHEMBL22312090 0.72 NOTUM (0.84) NOTUMCNR2DRD2DRD4
SCHEMBL27329801 0.72 NOTUM (0.47) NOTUMALOX5CNR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271938-A1 BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES CAPELLA THERAPEUTICS, INC. 2023-08-31 — — US disclosed
WO-2022081925-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2022-04-21 — — WO disclosed
US-9585884-B2 Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 AUSPEX PHARMACEUTICALS, INC. (US) 2017-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271938-A1 BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES CHKB, CHKA, CHUK NOTUM 694/4885HTR2C 2768/4885HTR2B 3047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback